Molecular diagnostics company BillionToOne Inc (NASDAQ:BLLN) reported fourth-quarter financial results that handily exceeded analyst expectations, driven by explosive growth across its core prenatal and oncology testing businesses. The company also raised its revenue guidance for the full year 2026, signaling continued confidence in its growth trajectory. The market reacted positively to the news, with shares trading higher in after-hours activity.
Earnings and Revenue Beat
For the quarter ended December 31, 2025, BillionToOne posted significant beats on both the top and bottom lines.
- Revenue: Reported $96.1 million, a 113% increase year-over-year, surpassing the analyst consensus estimate of approximately $88.9 million.
- Earnings Per Share (EPS): Reported non-GAAP diluted EPS of $0.11, exceeding the estimated $0.0866.
The strong quarterly performance capped off a transformative year for the company, with full-year 2025 revenue reaching $305.1 million, doubling the prior year's total of $152.6 million.
Key Drivers of Performance
The earnings release highlighted several factors behind the robust results:
- Dual Engine Growth: Both the prenatal and oncology segments delivered substantial increases. Prenatal clinical testing revenue grew 99% year-over-year in Q4 to $86.1 million, while oncology clinical testing revenue surged more than eightfold to $9.1 million.
- Expanding Profitability: The company demonstrated significant operating leverage. Gross profit margin expanded to 71% in Q4 2025, up from 57% a year ago. This improvement, coupled with disciplined expense growth, allowed BillionToOne to swing to an operating income of $10.3 million in the quarter, compared to an operating loss of $11.7 million in Q4 2024.
- Volume and Pricing Strength: Growth was fueled by a 47% increase in total tests delivered and a 47% rise in the overall average selling price (ASP) per test.
Raised 2026 Guidance
Management provided an optimistic outlook, raising its full-year 2026 revenue guidance. The company now expects revenue in the range of $430 million to $445 million, representing 41% to 46% growth over 2025. This new range is above the previous guidance of $415 million to $430 million and aligns closely with the analyst sales consensus estimate of approximately $413.2 million for the year. BillionToOne also expects to generate positive GAAP operating income for the full year 2026.
Market Reaction and Strategic Position
The positive earnings report and upgraded guidance were met with a favorable market response, with the stock rising over 5% in after-market trading. This move suggests investors are encouraged by the company's ability to not only grow revenue at a triple-digit pace but also translate that growth into meaningful profitability. The company ended the year with a strong balance sheet, holding approximately $496.0 million in cash and cash equivalents, which provides ample resources to fund continued expansion and product launches.
Product Pipeline and Recent Launches
The press release also noted recent operational milestones, including the February 2026 launch of expanded fetal antigen non-invasive prenatal tests (NIPT) and new oncology applications for its Northstar Select test. These launches are aimed at addressing critical decision points in prenatal care and cancer therapy selection, potentially opening new revenue streams.
Conclusion
BillionToOne's fourth-quarter results underscore a company in a powerful growth phase, successfully scaling its unique molecular counting technology across two large diagnostic markets. The substantial beats on revenue and earnings, coupled with raised guidance that meets or exceeds street expectations, paint a picture of strong execution and expanding financial health. The market's initial reaction reflects approval of this transition toward sustainable, profitable growth.
For a detailed look at BillionToOne's historical earnings and future analyst estimates, you can review the data here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, nor does it recommend buying or selling any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
